[MAYBANK] QoQ TTM Result on 31-Mar-2021 [#1]

Announcement Date
27-May-2021
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2021
Quarter
31-Mar-2021 [#1]
Profit Trend
QoQ- 5.28%
YoY- -19.14%
View:
Show?
TTM Result
31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 30/09/20 30/06/20 CAGR
Revenue 45,959,390 46,946,704 49,555,536 50,007,731 51,013,933 51,750,148 51,828,282 -7.67%
PBT 10,886,595 10,158,532 10,501,010 9,030,705 8,656,956 9,928,430 9,965,362 6.05%
Tax -2,565,080 -2,318,674 -2,389,534 -1,925,635 -1,937,877 -2,282,427 -2,284,083 8.01%
NP 8,321,515 7,839,858 8,111,476 7,105,070 6,719,079 7,646,003 7,681,279 5.46%
-
NP to SH 8,096,229 7,576,763 7,844,493 6,823,699 6,481,219 7,392,944 7,439,321 5.78%
-
Tax Rate 23.56% 22.82% 22.76% 21.32% 22.39% 22.99% 22.92% -
Total Cost 37,637,875 39,106,846 41,444,060 42,902,661 44,294,854 44,104,145 44,147,003 -10.06%
-
Net Worth 85,785,748 83,885,667 82,869,597 83,826,660 84,436,116 83,289,500 82,083,299 2.97%
Dividend
31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 30/09/20 30/06/20 CAGR
Div 6,784,472 7,549,914 9,067,498 5,845,508 5,845,508 5,901,714 4,384,131 33.68%
Div Payout % 83.80% 99.65% 115.59% 85.66% 90.19% 79.83% 58.93% -
Equity
31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 30/09/20 30/06/20 CAGR
Net Worth 85,785,748 83,885,667 82,869,597 83,826,660 84,436,116 83,289,500 82,083,299 2.97%
NOSH 11,878,513 11,693,337 11,693,337 11,413,994 11,241,361 11,241,361 11,241,361 3.73%
Ratio Analysis
31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 30/09/20 30/06/20 CAGR
NP Margin 18.11% 16.70% 16.37% 14.21% 13.17% 14.77% 14.82% -
ROE 9.44% 9.03% 9.47% 8.14% 7.68% 8.88% 9.06% -
Per Share
31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 30/09/20 30/06/20 CAGR
RPS 387.03 401.48 430.65 438.13 453.81 460.35 461.05 -10.98%
EPS 68.18 64.80 68.17 59.78 57.66 65.77 66.18 1.99%
DPS 57.13 64.57 78.80 52.00 52.00 52.50 39.00 28.89%
NAPS 7.2241 7.1738 7.2016 7.3442 7.5112 7.4092 7.3019 -0.70%
Adjusted Per Share Value based on latest NOSH - 11,413,994
31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 30/09/20 30/06/20 CAGR
RPS 380.95 389.14 410.76 414.51 422.85 428.95 429.60 -7.67%
EPS 67.11 62.80 65.02 56.56 53.72 61.28 61.66 5.79%
DPS 56.24 62.58 75.16 48.45 48.45 48.92 36.34 33.68%
NAPS 7.1107 6.9532 6.869 6.9483 6.9988 6.9038 6.8038 2.97%
Price Multiplier on Financial Quarter End Date
31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 30/09/20 30/06/20 CAGR
Date 31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 30/09/20 30/06/20 -
Price 8.30 8.05 8.11 8.25 8.46 7.22 7.51 -
P/RPS 2.14 2.01 1.88 1.88 1.86 1.57 1.63 19.84%
P/EPS 12.17 12.42 11.90 13.80 14.67 10.98 11.35 4.74%
EY 8.21 8.05 8.41 7.25 6.82 9.11 8.81 -4.58%
DY 6.88 8.02 9.72 6.30 6.15 7.27 5.19 20.61%
P/NAPS 1.15 1.12 1.13 1.12 1.13 0.97 1.03 7.60%
Price Multiplier on Announcement Date
31/12/21 30/09/21 30/06/21 31/03/21 31/12/20 30/09/20 30/06/20 CAGR
Date 24/02/22 25/11/21 26/08/21 27/05/21 25/02/21 27/11/20 27/08/20 -
Price 8.70 8.11 8.45 8.33 8.09 8.29 7.46 -
P/RPS 2.25 2.02 1.96 1.90 1.78 1.80 1.62 24.40%
P/EPS 12.76 12.52 12.40 13.93 14.03 12.61 11.27 8.60%
EY 7.84 7.99 8.07 7.18 7.13 7.93 8.87 -7.87%
DY 6.57 7.96 9.33 6.24 6.43 6.33 5.23 16.37%
P/NAPS 1.20 1.13 1.17 1.13 1.08 1.12 1.02 11.41%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ & YoY figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment